Clinical Trials Logo

Glucose Intolerance clinical trials

View clinical trials related to Glucose Intolerance.

Filter by:

NCT ID: NCT02744976 Completed - Clinical trials for Coronary Artery Disease

Coronary Artery Disease Progression in Patients With Prediabetes

Start date: February 2016
Phase: Phase 4
Study type: Interventional

Prediabetes is a disorder of glucose metabolism that reflects the natural history of progression from normoglycaemia to type 2 diabetes mellitus. Patients with prediabetes have impaired glucose regulation caused by insulin resistance (IR). IR in patients undergoing percutaneous coronary intervention (PCI) is associated with coronary artery remodeling and coronary plaque vulnerability by intravascular ultrasound (IVUS) analysis. In stent restenosis after bare metal and drug-eluting stent implantation more frequently is observed in patients with high fasting-insulin levels and IR. Although IR has a significant role in the progression of atherosclerosis in prediabetic patients, the importance of managing prediabetes is often under-appreciated by clinicians. To date, no pharmacological treatment has been officially approved for prediabetes. According to American Diabetes Association recommendations, metformin is the only drug that could be considered in the treatment of prediabetic patients with a high risk of developing diabetes. Metformin is a safe and inexpensive glucose lowering drug that attenuates mortality and future cardiovascular events in patients with type 2 diabetes as well as the progression of atherosclerosis in non-diabetic animal models. This study was designed to analyze coronary plaque characteristics by iMAP IVUS in patients with and without prediabetes undergoing PCI and to evaluate the impact of metformin treatment on coronary plaque characteristics in prediabetic patients at 24 month follow up. The study hypothesis is that more pronounced coronary atherosclerosis progression as well as in-stent neointimal hyperplasia will be observed in patients with prediabetes. Metformin treatment attenuates the progression of atherosclerosis in patients with prediabetes.

NCT ID: NCT02742662 Completed - Obesity Clinical Trials

Smart Technology for Weight Loss and Metabolic Health

Start date: April 2016
Phase: N/A
Study type: Interventional

The study will evaluate whether a technology-based lifestyle intervention program using primarily a smartphone platform is an acceptable and effective way for treating obesity. The goal of the program is to achieve weight loss and enhance the health of overweight or obese subjects by improving their diet and activity via smartphone applications as compared with conventional in-person weight management programs.

NCT ID: NCT02720393 Completed - Prediabetes Clinical Trials

Impact of No-carrageenan Diet on Glucose Tolerance in Prediabetes

Start date: February 2016
Phase: N/A
Study type: Interventional

Participants will be randomly assigned to either regular or no-carrageenan prepared diets to determine whether the no-carrageenan leads to improvement in glucose tolerance. Hemoglobin A1c is the primary outcome measure.

NCT ID: NCT02708966 Completed - Clinical trials for Impaired Glucose Tolerance

Effect of Gymnema Sylvestre on Patients With Impaired Glucose Tolerance.

Start date: March 2016
Phase: Phase 2
Study type: Interventional

Prediabetes (PD) was defined as an state in which glucose levels are above normal but not enough to meet criteria for the diagnosis of type 2 diabetes (T2D). PD can be presented as impaired fasting glucose (IFG), impaired glucose tolerance (IGT) and glycated hemoglobin A1c (A1C) altered. The International Diabetes Federation (IDF) reported that in 2013 the prevalence of IGT was 6.9% which is equivalent to approximately 316 million individuals with IGT, it is expected that by 2035 this number will increase to 417 million people affected. Many hypoglycemic effects attributed to Gymnema sylvestre have been reported, including: increase of insulin secretion, regeneration of pancreatic islet cells, increased glucose utilization in various ways and inhibition of glucose uptake in the intestine.

NCT ID: NCT02706821 Completed - Prediabetes Clinical Trials

Anti-diabetic Effects of Persimmon Leaf Extract

Start date: February 2014
Phase: N/A
Study type: Interventional

The investigators performed a 8-week, randomized, double-blind, placebo-controlled crossover human trial to evaluate the efficacy and safety of persimmon leaf extract on blood glucose. The investigators measures changes in diabetes associated parameters, including fasting blood glucose, postprandial blood glucose, insulin, C-peptide and HbA1c.

NCT ID: NCT02706093 Completed - Glucose Intolerance Clinical Trials

Metabolic Adaptations in Response to High Intensity Interval Training in Obese Adults

HT
Start date: May 3, 2016
Phase: N/A
Study type: Interventional

The overall objectives are to: 1. Assess mechanisms underlying HIIT-induced improvements in insulin resistance at the whole-body, tissue, and cellular levels. 2. Systematically compare different HIIT regimens to help identify effective "doses" of HIIT that may be optimal for improving metabolic health in obese adults. 3. Assess the ability/willingness of obese subjects to adhere to a long-term HIIT program. Findings from these studies will greatly expand knowledge about the effects of HIIT on metabolic health, and will provide valuable information for development of programs aimed at maximizing key metabolic benefits of exercise.

NCT ID: NCT02702245 Completed - Glucose Intolerance Clinical Trials

Effects of Two Doses of Thylakoids on OGTT

Start date: January 2014
Phase: N/A
Study type: Interventional

This cross-over intervention study aims to investigate the effect of two doses of thylakoids to an oral glucose tolerance test (OGTT) on glucose and insulin homeostasis as well as appetite regulating hormones in healthy volunteers.

NCT ID: NCT02700334 Completed - Prediabetes Clinical Trials

Effect of Dapagliflozin on Insulin Secretion and Insulin Sensitivity in Patients With Prediabetes

Start date: October 2016
Phase: Phase 4
Study type: Interventional

Prediabetes is a term that refers to alterations in glucose homeostasis, including impaired fasting glucose (IFG), impaired glucose tolerance (IGT) or both, involving a higher risk of progression type 2 diabetes mellitus (T2DM). Dapagliflozin is a selective and reversible inhibitor of sodium-glucose type 2 (SGLT-2) co-transporter, which reduces renal glucose reabsorption and promotes the glucose excretion through urine, so that the blood glucose is improved in patients with T2DM. Although this mechanism is independent of insulin, there are evidence of improved secretion and insulin sensitivity, so it is interesting to assess these effects in patients with prediabetes, as potential therapy for treating such disorders and prevent progression to T2DM. The aim of this study is to evaluate the effect of Dapagliflozin on insulin secretion and insulin sensitivity in patients with prediabetes. The investigators hypothesis is that the administration of dapagliflozin improve insulin secretion and insulin sensitivity in patients with prediabetes.

NCT ID: NCT02695433 Completed - Metabolic Syndrome Clinical Trials

Replacing Refined Carbohydrates With Healthy Fats on Cardio-metabolic Markers

AV2
Start date: March 1, 2016
Phase: N/A
Study type: Interventional

The primary goal is to to characterize the effects of consuming 1 avocado fruit 7 days / week (5-7 days is acceptable) compared to a no avocado relatively low fat, carbohydrate control treatment over a 12 week period on insulin sensitivity as measured by the Matsuda composite index of insulin sensitivity (MISI).

NCT ID: NCT02689765 Completed - Type 2 Diabetes Clinical Trials

Effect of Anthocyanins on Metabolic Profiles in Subjects With Pre-diabetes

Start date: February 2016
Phase: Phase 4
Study type: Interventional

Metabolic problems represent one of the major health concerns which are attractive for being addressed by nutritional interventions, as these are directly connected to dietary habits.Anthocyans possess cardiovascular disease prevention, obesity control, and diabetes alleviation properties, but association between anthocyans and prediabetes need to be more firmly understood and established from robust clinical data. However, there is little human research that has reported on the efficacy of increased anthocyans bioactive consumption on insulin sensitivity in pre-diabetes.